Boehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the company to seek approval for the asset in a second condition. Topline data ...
Boehringer Ingelheim and ExpressionEdits will collaborate on the optimization of the expression of gene therapies ExpressionEdits announced a collaboration and licensing agreement with Boehringer ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback